← All trials
NCT06823479
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 14, 2025
- Primary completion
- Feb 28, 2029
- Completion date
- Feb 28, 2029
- First posted
- Feb 12, 2025
- Last posted
- May 29, 2025
- Enrollment
- 41
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Netherlands Cancer InstituteLead sponsor
- Netherlands Cancer InstituteOfficial
- Utrecht UniversityCollaborator
- Maastricht UniversityCollaborator
- Free University of AmsterdamCollaborator
- Erasmus University RotterdamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.